×
Market Insider

The charts show biotech could still break higher

Regeneron Pharmaceuticals
Mike Segar | Reuters

As political pressure appears to mount on biotech stocks, some technical analysts say the foundation for a bounce may be building.

"What I'm seeing is a basing situation here that I think by year-end could trade up to $340 or beyond," said John Kosar, director of research at Asbury Research.

The iShares Nasdaq Biotechnology ETF (IBB) traded near $287 a share midday Thursday, up slightly on the day but down roughly 15 percent for the year so far.